Bangsheng Hu1, Lianxiang Jiang1, Haixia Tang2, Meizhu Hu1, Jun Yu1, Zeping Dai3. 1. Department of Anesthesiology, The First Affiliated Hospital of Wannan Medical College, No.2, West Road of Zheshan, Wuhu, 241000, Anhui, China. 2. Department of Cardiology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China. 3. Department of Anesthesiology, The First Affiliated Hospital of Wannan Medical College, No.2, West Road of Zheshan, Wuhu, 241000, Anhui, China. zpdai@wnmc.edu.cn.
Abstract
OBJECTIVE: To evaluates the efficacy and safety of rivaroxaban versus aspirin in prevention of venous thromboembolism (VTE) following total hip (THA) or knee arthroplasty (TKA) or hip fracture surgery. METHODS: Major databases were systematically searched for all relevant studies published in English up to October 2020. The meta-analysis was conducted using RevMan 5.3 software. RESULTS: In total, 7 studies were retrieved which contained 5133 patients. Among these patients, 2605 patients (50.8%) received rivaroxaban, whereas 2528 patients (49.2%) received aspirin. There were no statistical difference between aspirin and rivaroxaban for reducing VTE (RR = 0.75, 95% CI 0.50-1.11, I2 = 36%, p = 0.15), major bleeding (RR = 0.94, 95% CI 0.45-2.37, I2 = 21%, p = 0.95), and all-cause mortality (RR = 0.88, 95% CI 0.12-6.44, I2 = 0%, p = 0.90) between the two groups. Compared with aspirin, rivaroxaban significantly increased nonmajor bleeding (RR = 1.29, 95% CI 1.05-1.58, I2 = 0%, p = 0.02). CONCLUSION: There was no significant difference between aspirin and rivaroxaban in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery. Aspirin may be an effective, safe, convenient, and cheap alternative for prevention of VTE. Further large randomized studies are required to confirm these findings.
OBJECTIVE: To evaluates the efficacy and safety of rivaroxaban versus aspirin in prevention of venous thromboembolism (VTE) following total hip (THA) or knee arthroplasty (TKA) or hip fracture surgery. METHODS: Major databases were systematically searched for all relevant studies published in English up to October 2020. The meta-analysis was conducted using RevMan 5.3 software. RESULTS: In total, 7 studies were retrieved which contained 5133 patients. Among these patients, 2605 patients (50.8%) received rivaroxaban, whereas 2528 patients (49.2%) received aspirin. There were no statistical difference between aspirin and rivaroxaban for reducing VTE (RR = 0.75, 95% CI 0.50-1.11, I2 = 36%, p = 0.15), major bleeding (RR = 0.94, 95% CI 0.45-2.37, I2 = 21%, p = 0.95), and all-cause mortality (RR = 0.88, 95% CI 0.12-6.44, I2 = 0%, p = 0.90) between the two groups. Compared with aspirin, rivaroxaban significantly increased nonmajor bleeding (RR = 1.29, 95% CI 1.05-1.58, I2 = 0%, p = 0.02). CONCLUSION: There was no significant difference between aspirin and rivaroxaban in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery. Aspirin may be an effective, safe, convenient, and cheap alternative for prevention of VTE. Further large randomized studies are required to confirm these findings.
Authors: Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Sadhbh Ní Cheallaigh; Aoife Fleming; Darren Dahly; Eimear Kehoe; John M O'Byrne; Brid McGrath; Charles O'Connell; Laura J Sahm Journal: Int J Clin Pharm Date: 2020-04-23
Authors: Jeffrey I Weitz; Anthonie W A Lensing; Martin H Prins; Rupert Bauersachs; Jan Beyer-Westendorf; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Maria C S Freitas; Gerlind Holberg; Ajay K Kakkar; Lloyd Haskell; Bonno van Bellen; Akos F Pap; Scott D Berkowitz; Peter Verhamme; Philip S Wells; Paolo Prandoni Journal: N Engl J Med Date: 2017-03-18 Impact factor: 91.245
Authors: Gulraj S Matharu; Setor K Kunutsor; Andrew Judge; Ashley W Blom; Michael R Whitehouse Journal: JAMA Intern Med Date: 2020-03-01 Impact factor: 21.873
Authors: David R Anderson; Michael J Dunbar; Eric R Bohm; Etienne Belzile; Susan R Kahn; David Zukor; William Fisher; Wade Gofton; Peter Gross; Stephane Pelet; Mark Crowther; Steven MacDonald; Paul Kim; Susan Pleasance; Nicki Davis; Pantelis Andreou; Philip Wells; Michael Kovacs; Marc A Rodger; Tim Ramsay; Marc Carrier; Pascal-Andre Vendittoli Journal: Ann Intern Med Date: 2013-06-04 Impact factor: 25.391
Authors: Jose Luiz Colleoni; Fernando Noel Ribeiro; Paulo Augusto Castro Mos; João Paulo Reis; Henrique Rosa de Oliveira; Beatriz Kawata Miura Journal: Rev Bras Ortop Date: 2017-12-06